Depomed Inc. said it received a favorable court decision on its patents for its Nucynta painkiller products and expected the ruling would result in market exclusivity through 2025.
WSJ.com: Health, Wall Street Journal: Business: Health
Fri, 09/30/2016 - 2:40pm
Depomed Inc. said it received a favorable court decision on its patents for its Nucynta painkiller products and expected the ruling would result in market exclusivity through 2025.